v3.26.3
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:        
Research and collaboration revenue $ 1,899 $ 795 $ 4,972 $ 3,150
Operating Expenses:        
Research and development 11,434 9,850 32,411 30,339
General and administrative 4,494 4,596 13,041 12,590
Total operating expenses 15,928 14,446 45,452 42,929
Loss from operations (14,029) (13,651) (40,480) (39,779)
Other (expense) income, net:        
Interest income 984 423 2,701 1,464
Change in fair value of derivative tranche liability (15,812) (1,800) (42,930) (1,800)
Other (expense) income (99) (71) (108) (4)
Total other (expense) income, net (14,927) (1,448) (40,337) (340)
Net loss $ (28,956) $ (15,099) $ (80,817) $ (40,119)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.37) $ (0.55) $ (1.24) $ (1.78)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.37) $ (0.55) $ (1.24) $ (1.78)
Weighted-average shares of common stock outstanding, basic (in shares) 78,945,521 27,274,721 65,009,956 22,554,427
Weighted-average common shares outstanding, diluted (in shares) 78,945,521 27,274,721 65,009,956 22,554,427
Net loss attributable to common stockholders $ (28,956) $ (15,099) $ (80,817) $ (40,119)
Other comprehensive income (loss) 0 0 0 0
Total comprehensive loss $ (28,956) $ (15,099) $ (80,817) $ (40,119)